Inhibitor Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
INTIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
We have elected not to include a summary pursuant to this Item 16.
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm – Cherry Bekaert LLP (PCAOB ID 677) | F-2 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Statements of Operations for the years ended December 31, 2023 and 2022 | F-4 |
| Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022 | F-5 |
| Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.